DXCM

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DexCom, Inc.  DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 performance and a robust international foothold are expected to contribute further.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes market. DXCM aims to expand CGM adoption to Type 2 non-insulin patients, but commercial uptake remains unproven despite positive clinical trial results. At 28x earnings, DXCM's valuation is not demanding, yet offers limited upside given execution risks and the need for evidence of new market penetration.

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it the stronger stock to watch now.

DXCM's redesigned Stelo app is set for a July U.S. rollout, with international expansion and pediatric clearance broadening its glucose insights push.

Until recently, it had been a lackluster year for the healthcare sector. From high medical utilization squeezing insurers to structural cost pressures and valuation hangovers, medical stocks stocks have lagged much of the broader market this year.

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.